Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18443334 | 0.91 | NR1H2 (0.38) | NR1H2NR1H3CHRM2CHRM4CHRM1 | |
| SCHEMBL18439925 | 0.87 | NR1H2 (0.38) | NR1H2NR1H3CHRM2CHRM4CHRM1 | |
| SCHEMBL18443554 | 0.85 | NR1H2 (0.39) | NR1H2NR1H3TRPV3CHRM2CHRM4 | |
| SCHEMBL18441917 | 0.85 | CSNK1D (0.38) | NR1H2NR1H3 | |
| SCHEMBL2873485 | 0.83 | NR1H2 (0.40) | NR1H2NR1H3TRPV3CHRM2CHRM4 | |
| SCHEMBL18443543 | 0.83 | NR1H2 (0.37) | NR1H2NR1H3CHRM2CHRM4CHRM1 | |
| SCHEMBL18443868 | 0.83 | MAPK14 (0.40) | NR1H2 | |
| SCHEMBL18485182 | 0.82 | NR1H2 (0.41) | NR1H2NR1H3TRPV3CHRM2CHRM4 | |
| SCHEMBL20423209 | 0.81 | NR1H2 (0.34) | NR1H2NR1H3 | |
| SCHEMBL18437192 | 0.81 | GRIA1 (0.39) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604512-B2 | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-10166218-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-10166218-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-02 | — | — | US | disclosed |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-02 | — | — | US | disclosed |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-02 | — | — | US | disclosed |
| WO-2017024026-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023986-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023973-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023986-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023973-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NR1H2 1517/4885NR1H3 1639/4885TRPV3 782/4885 |
| US-10166218-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NR1H2 3679/4885NR1H3 3729/4885TRPV3 1350/4885 |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NR1H2 3567/4885NR1H3 3626/4885TRPV3 1253/4885 |
| US-10604512-B2 | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | NR1H2 2418/4885NR1H3 2403/4885TRPV3 414/4885 |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NR1H2 3601/4885NR1H3 3662/4885TRPV3 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.